We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Coloplast AS | TG:CBHD | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 0.44% | 113.85 | 113.70 | 113.85 | 114.15 | 113.05 | 113.95 | 466 | 08:12:39 |
Coloplast announces financial guidance for the 2023/24 financial year. Organic revenue growth is expected around 8% and the EBIT margin is expected at 27-28%. The assumptions on the financial guidance are laid out below.
Organic growth is expected around 8% in constant currencies. The guidance assumes growth across business areas and regions to be largely in line with the Strive25 ambitions, except for China.
Reported growth in DKK is expected to be around 12% and assumes:
The reported EBIT margin before special items is expected at 27-28%, and includes the following assumptions:
Special items are expected to be around DKK 50 million in FY 2023/24, related to the integration of Atos Medical.
Capital expenditures are expected to be around DKK 1.4 billion. The effective tax rate is expected to be around 22%.
Forward-looking statementsThe forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict.The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time.Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company’s financial results.
For further information, please contact
Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111
Aleksandra DimovskaSenior Director, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@coloplast.com
Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@coloplast.com
Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@coloplast.com
AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917
Websitewww.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.
Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2023-11.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachment
1 Year Coloplast AS Chart |
1 Month Coloplast AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions